Table 9. .

Replication Study to Validate Low GCN of Total C4 or C4A as Risk Factor for and High GCN as Protective Factor against SLE in European Americans

Gene, Patients, and GCN	OR (95% CI)	Pa
Total C4:
Ohiob:
2 or 3	1.823 (1.287–2.583)	.001
4	.737 (.527–1.030)	.087
5 or 6	.466 (.246–.882)	.016
SPc:
2 or 3	1.666 (1.087–2.554)	.024
4	.783 (.518–1.184)	.289
5 or 6	.520 (.239–1.132)	.129
C4A:
Ohiob:
0 or 1	2.024 (1.384–2.959)	.0003
2	.825 (.590–1.153)	.268
3, 4, or 5	.574 (.370–.890)	.012
SPc:
0 or 1	2.121 (1.352–3.326)	.001
2	.926 (.612–1.400)	.752
3, 4, or 5	.391 (.210–.729)	.002

^aP value calculated by Fisher’s exact test.

^bProspective European American patients with SLE who are from Ohio.

^cIndependent European American patients with SLE who were part of a replication study.